FDA approval arrived.
Has anyone checked the patent-term-extension deadline?
The filing window is generally 60 days, with approval normally counted as day one. Miss it, and the opportunity for additional patent term may be lost.
Patent term extension can restore some of the patent life lost during regulatory review. Under Section 156 of the Patent Act, eligible patents covering approved drugs, biologics, or certain medical devices may qualify.
But the extra time is not automatic.
An extension can add up to five years. The remaining patent term plus the extension is limited to fourteen years after approval.
The filing deadline deserves particular attention.
The 60-day period cannot be extended. Special counting rules apply to approvals transmitted late in the day or on nonbusiness days.
Have patent counsel calculate the deadline from the actual approval notice, not the press release.
Eligibility matters, too.
The patent must claim the approved product, a method of using it, or a method of manufacturing it. Having a patent on related technology does not automatically qualify.
Only one patent can be extended for the same regulatory review period for a product. If several patents may qualify, compare their claim coverage, expiration dates, and potential extensions.
Protection during the extended period is also limited by Section 156. Do not assume every product or use covered during the original term remains protected.
An extension provides additional patent protection, not a guarantee of a competition-free market.
Practical takeaway: for pharmaceutical and medical-device companies, connect the regulatory and patent calendars before approval is expected.
Identify the candidate patents. Assign responsibility for preparing the extension request. Arrange for the regulatory team to send the approval notice to patent counsel as soon as it arrives.
Then calculate and record the actual deadline.
There is a drafting connection, too.
When developing the patent portfolio, consider how the claims relate to the product moving through regulatory review. Discuss protection for the product, its uses, and its manufacturing methods where the application supports those claims.
Those choices may matter later when assessing which patents qualify for an extension.
FDA approval is a major milestone.
It should trigger a patent-deadline check, not just a launch announcement.
If approval has already arrived and nobody has raised the extension, have patent counsel check the deadline now.
Sources
USPTO, Patent Term Extension Under 35 U.S.C. 156. USPTO
https://www.uspto.gov/patents/laws/patent-terms-extended
35 U.S.C. 156, Extension of Patent Term. Legal Information Institute
https://www.law.cornell.edu/uscode/text/35/156
USPTO, MPEP 2754.01, Deadline for Filing an Application Under 35 U.S.C. 156(d)(1). USPTO
https://www.uspto.gov/web/offices/pac/mpep/s2754.html
USPTO, MPEP 2761, Multiple Applications for Patent Term Extension. USPTO
https://www.uspto.gov/web/offices/pac/mpep/s2761.html






